Lonza licenses dual-payload ADC technology to Antharis for GI cancer programs
Swiss contract development and manufacturing organization (CDMO) Lonza Group (SWX: LONN) has signed an exclusive, target-specific licensing agreement with US biotech Antharis Therapeutics to develop dual-payload antibody-drug conjugates (ADCs) for gastrointestinal (GI) cancers.
Under the agreement, Antharis will gain rights to Lonza’s site-specific dual-payload ADC technology, which is designed to deliver two distinct therapeutic payloads through a single antibody. The companies said the approach could help address tumor heterogeneity and drug resistance, two challenges that can limit the effectiveness of conventional single-payload ADCs.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
| Headless Content Management with Blaze